These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27413042)

  • 1. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial.
    Akinkuolie AO; Glynn RJ; Padmanabhan L; Ridker PM; Mora S
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27413042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk.
    Lawler PR; Akinkuolie AO; Chandler PD; Moorthy MV; Vandenburgh MJ; Schaumberg DA; Lee IM; Glynn RJ; Ridker PM; Buring JE; Mora S
    Circ Res; 2016 Apr; 118(7):1106-15. PubMed ID: 26951635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group IIA Secretory Phospholipase A
    Akinkuolie AO; Lawler PR; Chu AY; Caulfield M; Mu J; Ding B; Nyberg F; Glynn RJ; Ridker PM; Hurt-Camejo E; Chasman DI; Mora S
    Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1182-1190. PubMed ID: 31070471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
    Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GlycA, a Pro-Inflammatory Glycoprotein Biomarker, and Incident Cardiovascular Disease: Relationship with C-Reactive Protein and Renal Function.
    Gruppen EG; Riphagen IJ; Connelly MA; Otvos JD; Bakker SJ; Dullaart RP
    PLoS One; 2015; 10(9):e0139057. PubMed ID: 26398105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel protein glycan biomarker and future cardiovascular disease events.
    Akinkuolie AO; Buring JE; Ridker PM; Mora S
    J Am Heart Assoc; 2014 Sep; 3(5):e001221. PubMed ID: 25249300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.
    Otvos JD; Guyton JR; Connelly MA; Akapame S; Bittner V; Kopecky SL; Lacy M; Marcovina SM; Muhlestein JB; Boden WE
    J Clin Lipidol; 2018; 12(2):348-355.e2. PubMed ID: 29409728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.
    Ridker PM; MacFadyen J; Cressman M; Glynn RJ
    J Am Coll Cardiol; 2010 Mar; 55(12):1266-1273. PubMed ID: 20206456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Everett BM; Caulfield MP; Hantash FM; Wohlgemuth J; Ridker PM; Mora S
    Circulation; 2014 Feb; 129(6):635-42. PubMed ID: 24243886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Muhlestein JB; May HT; Galenko O; Knowlton KU; Otvos JD; Connelly MA; Lappe DL; Anderson JL
    Am Heart J; 2018 Aug; 202():27-32. PubMed ID: 29803983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial.
    Dagenais GR; Jung H; Lonn E; Bogaty PM; Dehghan M; Held C; Avezum A; Jansky P; Keltai M; Leiter LA; Lopez-Jaramillo P; Toff WD; Bosch J; Yusuf S
    J Am Heart Assoc; 2018 Jul; 7(15):. PubMed ID: 30033433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.